Frontotemporal lobar degeneration

M Grossman, WW Seeley, AL Boxer, AE Hillis… - Nature Reviews …, 2023 - nature.com
Frontotemporal lobar degeneration (FTLD) is one of the most common causes of early-onset
dementia and presents with early social–emotional–behavioural and/or language changes …

Tau-targeting therapies for Alzheimer disease

EE Congdon, EM Sigurdsson - Nature Reviews Neurology, 2018 - nature.com
Alzheimer disease (AD) is the most common form of dementia. Pathologically, AD is
characterized by amyloid plaques and neurofibrillary tangles in the brain, with associated …

[HTML][HTML] Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target …

G Limorenko, HA Lashuel - Chemical Society Reviews, 2022 - pubs.rsc.org
Converging evidence continues to point towards Tau aggregation and pathology formation
as central events in the pathogenesis of Alzheimer's disease and other Tauopathies …

Role of Nrf2 in aging, Alzheimer's and other neurodegenerative diseases

M George, M Tharakan, J Culberson, AP Reddy… - Ageing Research …, 2022 - Elsevier
Abstract Nuclear Factor-Erythroid Factor 2 (Nrf2) is an important transcription factor that
regulates the expression of large number of genes in healthy and disease states. Nrf2 is …

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

T Dam, AL Boxer, LI Golbe, GU Höglinger, HR Morris… - Nature medicine, 2021 - nature.com
A randomized, double-blind, placebo-controlled, 52-week study (no. NCT03068468)
evaluated gosuranemab, an anti-tau monoclonal antibody, in the treatment of progressive …

Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases

E Beurel, SF Grieco, RS Jope - Pharmacology & therapeutics, 2015 - Elsevier
Abstract Glycogen synthase kinase-3 (GSK3) may be the busiest kinase in most cells, with
over 100 known substrates to deal with. How does GSK3 maintain control to selectively …

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches

AL Boxer, JT Yu, LI Golbe, I Litvan, AE Lang… - The Lancet …, 2017 - thelancet.com
Progressive supranuclear palsy (PSP), previously believed to be a common cause of
atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes …

[HTML][HTML] Tau protein interaction partners and their roles in Alzheimer's disease and other tauopathies

J Sinsky, K Pichlerova, J Hanes - International journal of molecular …, 2021 - mdpi.com
Tau protein plays a critical role in the assembly, stabilization, and modulation of
microtubules, which are important for the normal function of neurons and the brain. In …

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

GU Höglinger, I Litvan, N Mendonca, D Wang… - The Lancet …, 2021 - thelancet.com
Background Progressive supranuclear palsy is a neurodegenerative disorder associated
with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds …

A phase II trial of tideglusib in Alzheimer's disease

S Lovestone, M Boada, B Dubois… - Journal of …, 2015 - journals.sagepub.com
Background: The ARGO study was a phase II, double-blind, placebo controlled, four parallel
arm trial of tideglusib in Alzheimer's disease (AD). Objective: To prove the clinical efficacy of …